II期微卫星稳定结直肠癌的淋巴细胞浸润:回顾性预后生物标志物分析
本研究旨在评估T细胞浸润作为II期结直肠癌预后生物标志物的价值。通过T细胞受体免疫测序量化T细胞丰度和克隆性,在发现集及三个验证集中分析。结果显示较高的TCR丰度与更好的预后相关,而高克隆性指数(低多样性)在部分数据集中与较差预后相关,联合分析证实了这些关联。
要点
- 较高的TCR丰度与II期微卫星稳定结直肠癌更好的预后独立相关。
- 高克隆性指数(低多样性)在部分数据集中与较差的无病生存期相关。
- T细胞浸润可作为II期MSS结直肠癌的预后生物标志物。
核心结论
- 肿瘤淋巴细胞经TCR repertoire量化评估,是微卫星稳定II期结直肠癌的独立预后因素。
研究设计与样本
- 回顾性预后生物标志物分析,发现集95例II期微卫星稳定结肠癌患者,中位年龄67岁,30%女性。
- 验证集包括112例新鲜冷冻样本(中位年龄69岁,44%女性)和163例FFPE样本(中位年龄67岁,39%女性),均来自西班牙巴塞罗那。
- 另一验证集包括270例FFPE样本,来自以色列海法,中位年龄73岁,46%女性。
- 中位随访时间81.1个月,采用Cox回归模型评估预后价值,调整性别、年龄、肿瘤位置和分期(IIA和IIB)。
主要发现
- 在发现集中,较高的TCR丰度与更好的预后相关(HR for ≥Q1 = 0.25,95%CI 0.10-0.63,P=0.003)。
- 在独立FF数据集中,TCR丰度HR=0.30(95%CI 0.12-0.72,P=0.007),克隆性HR=3.32(95%CI 1.38-7.94,P=0.007)。
- 在两个独立FFPE数据集中,TCR丰度与预后相关(HR=0.41,95%CI 0.18-0.93,P=0.03;HR=0.56,95%CI 0.31-1,P=0.042)。
- 克隆性指数仅在以色列FFPE数据集中与预后相关(HR=2.45,95%CI 1.39-4.32,P=0.002)。
- 联合所有MSS样本分析显示TCR丰度(HR=0.39,95%CI 0.26-0.57,P=1.3e-06)和克隆性指数(HR=2.13,95%CI 1.44-3.15,P=0.0002)均有预后价值。
临床怎么用
- TCR丰度可作为II期MSS结直肠癌的预后标志物,辅助识别高风险患者。
- 高克隆性指数可能提示较差预后,但需进一步验证。
局限性
- 本研究为回顾性研究,样本保存方法不同。
- 验证系列缺乏完整的微卫星不稳定状态和病理评估信息。
- MECC研究提供的是总生存期信息而非无进展生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identifying stage II patients with colorectal cancer (CRC) at higher risk of progression is a clinical priority in order to optimize the advantages of adjuvant chemotherapy while avoiding unnecessary toxicity. Recently, the intensity and the quality of the host immune response in the tumor microenvironment have been reported to have an important role in tumorigenesis and an inverse association with tumor progression. This association is well established in microsatellite instable CRC. In this work, we aim to assess the usefulness of measures of T-cell infiltration as prognostic biomarkers in 640 stage II, CRC tumors, 582 of them confirmed microsatellite stable. METHODS AND FINDINGS: We measured both the quantity and clonality index of T cells by means of T-cell receptor (TCR) immunosequencing in a discovery dataset (95 patients with colon cancer diagnosed at stage II and microsatellite stable, median age 67, 30% women) and replicated the results in 3 additional series of stage II patients from 2 countries. Series 1 and 2 were recruited in Barcelona, Spain and included 112 fresh frozen (FF, median age 69, 44% women) and 163 formalin-fixed paraffin-embedded (FFPE, median age 67, 39% women) samples, respectively. Series 3 included 270 FFPE samples from patients recruited in Haifa, Northern Israel, as part of a large case-control study of CRC (median age 73, 46% women). Median follow-up time was 81.1 months. Cox regression models were fitted to evaluate the prognostic value of T-cell abundance and Simpson clonality of TCR variants adjusting by sex, age, tumor location, and stage (IIA and IIB). In the discovery dataset, higher TCR abundance was associated with better prognosis (hazard ratio [HR] for ≥Q1 = 0.25, 95% CI 0.10-0.63, P = 0.003). A functional analysis of gene expression on these tumors revealed enrichment in pathways related to immune response. Higher values of clonality index (lower diversity) were not associated with worse disease-free survival, though the HR for ≥Q3 was 2.32 (95% CI 0.90-5.97, P = 0.08). These results were replicated in an independent FF dataset (TCR abundance: HR = 0.30, 95% CI 0.12-0.72, P = 0.007; clonality: HR = 3.32, 95% CI 1.38-7.94, P = 0.007). Also, the association with prognosis was tested in 2 independent FFPE datasets. The same association was observed with TCR abundance (HR = 0.41, 95% CI 0.18-0.93, P = 0.03 and HR = 0.56, 95% CI 0.31-1, P = 0.042, respectively, for each FFPE dataset). However, the clonality index was associated with prognosis only in the FFPE dataset from Israel (HR = 2.45, 95% CI 1.39-4.32, P = 0.002). Finally, a combined analysis combining all microsatellite stable (MSS) samples demonstrated a clear prognosis value both for TCR abundance (HR = 0.39, 95% CI 0.26-0.57, P = 1.3e-06) and the clonality index (HR = 2.13, 95% CI 1.44-3.15, P = 0.0002). These associations were also observed when variables were considered continuous in the models (HR per log2 of TCR abundance = 0.85, 95% CI 0.78-0.93, P = 0.0002; HR per log2 or clonality index = 1.16, 95% CI 1.03-1.31, P = 0.016). LIMITATIONS: This is a retrospective study, and samples had been preserved with different methods. Validation series lack complete information about microsatellite instability (MSI) status and pathology assessment. The Molecular Epidemiology of Colorectal Cancer (MECC) study had information about overall survival instead of progression-free survival. CONCLUSION: Results from this study demonstrate that tumor lymphocytes, assessed by TCR repertoire quantification based on a sequencing method, are an independent prognostic factor in microsatellite stable stage II CRC.
引用
- Sanz-Pamplona R, Melas M, Maoz A, et al. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis. PLoS Med. 2020. PMID: 32970670. doi:10.1371/journal.pmed.1003292
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。